Search Results - "Llabrés, Elisenda"

Prediction of Unplanned Hospitalizations in Older Patients Treated with Chemotherapy by Feliu, Jaime, Espinosa, Enrique, Basterretxea, Laura, Paredero, Irene, Llabrés, Elisenda, Jiménez-Munárriz, Beatriz, Losada, Beatriz, Pinto, Alvaro, Custodio, Ana Belén, Muñoz, María Del Mar, Gómez-Mediavilla, Jeniffer, Torregrosa, María Dolores, Cruz, Patricia, Higuera, Oliver, Molina-Garrido, María José

“…To determine the incidence of unplanned hospitalization (UH) and to identify risk factors for UH in elderly patients with cancer who start chemotherapy. In…”
Get full text

Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR study by Falcón González, Alejandro, Cruz Jurado, Josefina, Llabrés Valenti, Elisenda, Urbano Cubero, Rocío, Álamo de la Gala, Maria Carmen, Martínez Guisado, María Antonia, Álvarez Ambite, Rocío, Rodríguez González, Carlos José, Amérigo Góngora, Marta, Rodríguez Pérez, Lourdes, López Álvarez, Pilar, Sánchez Rovira, Pedro, González Flores, Encarnación, Henao Carrasco, Fernando, Bayo Calero, Juan, Valero Arbizu, María, Quílez Cutillas, Alicia, Salvador Boffil, Javier, Rubio Pérez, Eloísa, Ruiz-Borrego, Manuel

“…Purpose HER2-targeted therapies have dramatically improved outcomes of patients with HER2-positive breast cancer (BC), as demonstrated in neoadjuvant trials…”
Get full text

Predicting Chemotherapy Toxicity in Older Patients with Cancer: A Multicenter Prospective Study by Feliu, Jaime, Jiménez‐Munárriz, Beatriz, Basterretxea, Laura, Paredero, Irene, Llabrés, Elisenda, Antonio‐Rebollo, Maite, Losada, Beatriz, Espinosa, Enrique, Gironés, Regina, Custodio, Ana Belén, del Mar Muñoz, María, Díaz‐Almirón, Mariana, Gómez‐Mediavilla, Jeniffer, Pinto, Alvaro, Torregrosa, María‐Dolores, Soler, Gema, Cruz, Patricia, Higuera, Oliver, Molina‐Garrido, María José

“…Background Standard oncology tools are inadequate to distinguish which older patients are at higher risk of developing chemotherapy‐related complications…”
Get full text

Prediction of Chemotoxicity, Unplanned Hospitalizations and Early Death in Older Patients with Colorectal Cancer Treated with Chemotherapy by Feliu, Jaime, Espinosa, Enrique, Basterretxea, Laura, Paredero, Irene, Llabrés, Elisenda, Jiménez-Munárriz, Beatriz, Antonio-Rebollo, Maite, Losada, Beatriz, Pinto, Alvaro, Custodio, Ana Belén, Del Mar Muñoz, María, Gómez-Mediavilla, Jenifer, Torregrosa, María-Dolores, Soler, Gema, Cruz, Patricia, Higuera, Oliver, Molina-Garrido, María-José

“…To identify risk factors for toxicity, unplanned hospitalization (UH) and early death (ED) in older patients with colorectal carcinoma (CRC) initiating…”
Get full text

Undertreatment and overtreatment in older patients treated with chemotherapy by Feliu, Jaime, Espinosa, Enrique, Basterretxea, Laura, Paredero, Irene, Llabrés, Elisenda, Jiménez-Munárriz, Beatriz, Antonio-Rebollo, Maite, Losada, Beatriz, Pinto, Alvaro, Gironés, Regina, Custodio, Ana Belén, Muñoz, María del Mar, Gómez-Mediavilla, Jenifer, Torregrosa, María Dolores, Soler, Gema, Cruz, Patricia, Higuera, Oliver, Molina-Garrido, María José

“…Inconsistent doses and schemes are commonly used in older patients receiving cancer chemotherapy. We performed this study in patients with cancer and…”
Get full text

Development and Validation of an Early Mortality Risk Score for Older Patients Treated with Chemotherapy for Cancer by Feliu, Jaime, Pinto, Alvaro, Basterretxea, Laura, López-San Vicente, Borja, Paredero, Irene, Llabrés, Elisenda, Jiménez-Munárriz, Beatriz, Antonio-Rebollo, Maite, Losada, Beatriz, Espinosa, Enrique, Gironés, Regina, Custodio, Ana Belén, Muñoz, María Del Mar, Díaz-Almirón, Mariana, Gómez-Mediavilla, Jenifer, Torregrosa, María Dolores, Soler, Gema, Cruz, Patricia, Higuera, Oliver, González-Montalvo, Juan Ignacio, Molina-Garrido, María José

“…Estimation of life expectancy in older patients is relevant to select the best treatment strategy. We aimed to develop and validate a score to predict early…”
Get full text

Abstract PS3-11: Correlation of pathological complete response and radiological response with Contrast-enhanced mammography in breast cancer patients after neoadjuvant chemotherapy by Valentí, Elisenda Llabrés, López, Jose Carlos Antela, Solís, Mónica Cejuela, de Liaño, Alfonso Gómez, Benítez, Victor Vega, Pavcovich, Marta, Medina, Concepción Jimenez, Sánchez, Joel Joselito Aranda, Rodriguez, Isabel Reyes, Betancor, Manuel Cazorla, Garcia, Maria Eugenia Galan, Hernández, Ana Alicia Tejera, Correa, Pedro Pérez, Rionda, Paula Junquera, Vaswani, Avinash Ramchandani, Rubio, Elena Vicente

“…Abstract Background: Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) has been reported as a surrogate endpoint for prediction of…”
Get full text

Abstract P1-18-29: Neopersur: Neoadjuvant pertuzumab in a real world data population in the south of Spain by González, Alejandro Falcón, Álvarez Ambite, Rocío, Valenti, Elisenda Llabrés, Cubero, Rocío Urbano, del Carmen Álamo de la Gala, Maria, Guisado, Antonia Martínez, González, Carlos José Rodríguez, Góngora, Marta Amérigo, Flores, Encarnación González, Casado, Salvador Gámez, Arbizu, María Valero, Cutillas, Alicia Quilez, Jurado, Josefina Cruz, Rovira, Pedro Sánchez, Carrasco, Fernando Henao, Bofill, Javier Salvador, Borrego, Manuel Ruiz

“…Abstract Background: Pertuzumab (P) has been aproved in neoadjuvant setting for HER2 positive early breasta cancer patients in association with Trastuzumab (T)…”
Get full text

P-0061 Docetaxel Monotherapy as a Second-Line Salvage Treatment in Advanced Gastric Cancer: Experience of 40 Patients with Prognostic Factor Analysis by Llabrés, Elisenda, Pérez, Martín Francisco Javier, Calvo, Mariona, Laquente, Berta, Vázquez, Silvia, Galán, Maica

Get full text

Comparative study of weekly and three-weekly neoadjuvant carboplatin in triple-negative breast cancer: retrospective analysis in real-world settings by Martin-Quesada, Ana Isabel, Llabres-Valentí, Elisenda, Montesdeoca-Godoy, Cristina María, Martín-Abreu, Carla, Alemán-Sánchez, Cristina, Rodríguez-Pérez, Natalia, Herrero-Márquez, Alicia, Cruz-Jurado, Josefina, Hernández-Sosa, María, Marrero-García, Melody, DelPino-Hernández, Cristina Victoria, Hernández-Sarmiento, Samuel José, Rodríguez-Capote, Alejandra, Pérez-Méndez, Lina, Núñez-Hernández, Isaac

“…Purpose Tri-weekly carboplatin is an established neoadjuvant treatment for triple-negative breast cancer, enhancing pathological complete response (pCR) and…”
Get full text

Pilot study to evaluate safety and efficacy of cabozantinib in aged fragile patients with metastatic renal cell carcinoma. Preliminary results of CABOMAYOR-SOGUG study by Climent Duran, Miguel Angel, Sánchez-Escribano, Ricardo, Llabres, Elisenda, Basterretxea, Laura, Torregrosa, Maria Dolores, Guzmán, José Carlos, Zambrana, Francisco, Fernández Núñez, Natalia, Heras, Lucía, Gironés, Regina

“…e16524 Background: Survival of patients with metastatic renal cell carcinoma (mRCC) has improved with targeted therapies, but they are rarely curative and…”
Get full text

Safety interim analysis (SIA) of atractib: A phase 2 trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC) by Cortes, Maria, Cortés Salgado, Alfonso, Morales Murillo, Serafin, Blancas, Isabel, Cortez, Patricia, Calvo Plaza, Isabel, Diaz Fernandez, Nieves, Martinez-Bueno, Alejandro, Ruiz-Borrego, Manuel, Blanch, Salvador, Llabres, Elisenda, Marmé, Frederik, Schmid, Peter, Guarneri, Valentina, Gligorov, Joseph, Pérez-García, José Manuel, Sampayo-Cordero, Miguel, Malfettone, Andrea, Llombart Cussac, Antonio, Cortes, Javier

“…1084 Background: A substantial benefit from adding an immune checkpoint inhibitor to chemotherapy (CT) was reported in mTNBC patients (pts) with PD-L1+ tumors…”
Get full text

Development and validation of an early death risk score for older patients treated with chemotherapy for cancer by Feliu Batlle, Jaime, Pinto, Alvaro, Basterretxea, Laura, Paredero Pérez, Irene, Llabres, Elisenda, Jimenez-Munarriz, Beatriz, Rebollo, Maite Antonio, Losada Vila, Beatriz, Espinosa, Enrique, Girones, Regina, Custodio, Ana B., Muñoz, María del Mar, Díaz-Almirón, Mariana, Gómez-Mediavilla, Jeniffer, Torregrosa, Maria Dolores, Soler, Gemma, Cruz, Patricia, Higuera, Oliver, Molina-Garrido, MJ

“…Abstract only 12030 Background: Determining life expectancy in older patients is needed to select the best treatment strategy. We aimed to develop and validate…”
Get full text

Predictors of chemotherapy modification at first cycle in elderly patient by Feliu Batlle, Jaime, Basterretxea, Laura, Paredero Pérez, Irene, Llabres, Elisenda, Losada Vila, Beatriz, Rebollo, Maite Antonio, Custodio, ANA Belen, Girones, Regina, Sanchez, Mar Munoz, Jimenez-Munarriz, Beatriz, Pinto, Alvaro, Telleria, Hellis, Saldana, Juana, Molina-Garrido, MJ

“…Abstract only…”
Get full text

Predictive factors of grade 3-5 toxicity in older patients with cancer treated with chemotherapy: A prospective multicenter study by Feliu Batlle, Jaime, Basterretxea, Laura, Torregrosa, Maria Dolores, Llabres, Elisenda, Losada Vila, Beatriz, Jimenez-Munarriz, Beatriz, Rebollo, Maite Antonio, Custodio, Ana B., Girones, Regina, Cruz, Patricia, Sanchez, Mar Munoz, Pinto, Alvaro, Soler, Gemma, Soria Comes, Teresa, Telleria, Hellis, Molina-Garrido, MJ

“…Abstract only 11509 Background: Older patients have increased risk of toxicity from chemotherapy. The purpose of this study was to analyse predictive factors…”
Get full text

Abstract PS16-02: Efficacy and safety of first-line atezolizumab + bevacizumab + paclitaxel in patients with advanced triple-negative breast cancer: the ATRACTIB phase 2 trial by Gion, Maria, Cortez-Castedo, Patricia, Blancas, Isabel, Cortés, Alfonso, Marmé, Frederik, Blanch, Salvador, Murillo, Serafin Morales, Díaz, Nieves, Calvo-Plaza, Isabel, Recalde, Sabela, Martínez-Bueno, Alejandro, Ruiz-Borrego, Manuel, Llabres, Elisenda, Taberner, María Teresa, de Laurentiis, Michelino, García-Sáenz, José Ángel, Repkova, Jana, Antón, Antonio, Gligorov, Joseph, Cruz, Susana de la, Hoffmann, Oliver, Medioni, Jacques, Phillips, Melissa, Sampayo-Cordero, Miguel, Alcalá-López, Daniel, Pérez-García, José Manuel, Llombart-Cussac, Antonio, Cortés, Javier

“…Abstract BACKGROUND Triple-negative breast cancer (TNBC) is an aggressive tumor characterized by poor outcomes and new treatment strategies are urgently…”
Get full text

Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trialResearch in context by Antonio Llombart-Cussac, José Manuel Pérez-Garcia, Manuel Ruiz Borrego, Pablo Tolosa, Salvador Blanch, Adela Fernández-Ortega, Ander Urruticoechea, Isabel Blancas, Cristina Saura, Beatriz Rojas, Begoña Bermejo, José Ponce Lorenzo, María Gion, Patricia Cortez-Castedo, Elisenda Llabres, Elena Galve, Juan Fernando Cueva, Ana López, José Luis Alonso-Romero, Santiago González-Santiago, Eduardo Martínez de Dueñas, Eva Ciruelos, Griselda Martrat, Petra Gener, Daniel Alcalá-López, Miguel Sampayo-Cordero, Fernando Gómez-Peralta, Javier Cortés

“…Background: Hyperglycaemia is an early and frequent adverse event during alpelisib treatment. METALLICA aimed to evaluate prophylactic metformin to prevent or…”
Get full text

Abstract PD8-02: Metformin (MET) for the prevention of Alpelisib (ALP)-related Hyperglycemia (HG) in PIK3CA-mutated, Hormone Receptor-Positive (HR[+]) HER2-Negative (HER2[-]) Advanced Breast Cancer (ABC): The METALLICA study by Borrego, Manuel Ruiz, Tolosa, Pablo, Blanch, Salvador, Fernández, Adela, Urriticoechea, Ander, Blancas, Isabel, Saura, Cristina, Rojas, Beatriz, Bermejo, Begoña, Ponce, Jose, Gión, Maria, Llabres, Elisenda, Galve, Elena, Cueva, Juan Fernando, López, Ana, Alonso-Romero, José L, González-Santiago, Santiago, De Dueñas, Eduardo Martínez, Peralta, Fernando Gomez, Ciruelos, Eva, Pérez-García, José Manuel, Llombart-Cussac, Antonio, Cortés, Javier

“…Abstract Background: HG is an on-target AE of PI3K inhibition, reported in 63.7% (36.6% G≥3) of HR[+]/HER2[-] ABC patients (pts) treated with ALP plus…”
Get full text

Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial by Llombart-Cussac, Antonio, Pérez-Garcia, José Manuel, Ruiz Borrego, Manuel, Tolosa, Pablo, Blanch, Salvador, Fernández-Ortega, Adela, Urruticoechea, Ander, Blancas, Isabel, Saura, Cristina, Rojas, Beatriz, Bermejo, Begoña, Ponce Lorenzo, José, Gion, María, Cortez-Castedo, Patricia, Llabres, Elisenda, Galve, Elena, Cueva, Juan Fernando, López, Ana, Alonso-Romero, José Luis, González-Santiago, Santiago, Martínez de Dueñas, Eduardo, Ciruelos, Eva, Martrat, Griselda, Gener, Petra, Alcalá-López, Daniel, Sampayo-Cordero, Miguel, Gómez-Peralta, Fernando, Cortés, Javier

“…Hyperglycaemia is an early and frequent adverse event during alpelisib treatment. METALLICA aimed to evaluate prophylactic metformin to prevent or reduce…”
Get full text